Kymab Wins UK Supreme Court Antibody Battle Against Regeneron
The UK Supreme Court has supported an appeal by British biotech Kymab to revoke antibody…
The UK Supreme Court has supported an appeal by British biotech Kymab to revoke antibody…
Update (04/06/2020): After upholding four of Kymab's patents addressing the production of antibody drugs earlier…
A genetic mutation common to Finnish populations has been found to protect against type 2…
ISA Pharmaceuticals will work together with Regeneron to combine its immunotherapy against cancer induced by…
Regeneron and Sanofi have announced positive early results from a Phase II study investigating their…
Update (01/10/2017): The European Commission has tighter control over pricing that governments have over here…
A new asthma drug developed by Sanofi and Regeneron, dupilumab, has met its primary objectives…
The FDA has granted breakthrough therapy designation to Regeneron and Sanofi for cemiplimab, just a…
After a run of successful therapeutic antibodies, including a potential blockbuster, Regeneron says it will…
UPDATE (27/06/2017): The EMA has followed suit by approving Kevzara for moderate to severe rheumatoid arthritis. UPDATE (23/05/2017): More…
Bayer's and Regeneron's blockbuster Eylea could be facing serious competition, as Novartis boasts with positive…
After Praluent, Sanofi and Regeneron have now scored their next drug approval with dupilumab, an antibody for the…